← FDA DRUG APPROVALS

FDA ANDA · ANDA077507

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

Sponsor: EPIC PHARMA LLC

APPLICATION
ANDA077507
TYPE
ANDA
ORIGINAL APPROVAL
2005-10-27
LATEST ACTION
2017-04-05
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

GLIPIZIDE AND METFORMIN HYDROCHLORIDEPrescription
GLIPIZIDE 2.5MG, METFORMIN HYDROCHLORIDE 500MG · TABLET · ORAL
GLIPIZIDE AND METFORMIN HYDROCHLORIDEPrescription
GLIPIZIDE 5MG, METFORMIN HYDROCHLORIDE 500MG · TABLET · ORAL
GLIPIZIDE AND METFORMIN HYDROCHLORIDEPrescription
GLIPIZIDE 2.5MG, METFORMIN HYDROCHLORIDE 250MG · TABLET · ORAL

Approval history

2017-04-05Labeling · Supplement 4 · standardAP
2010-08-26Labeling · Supplement 3AP
2009-10-26Labeling · Supplement 2AP
2005-10-27OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →